Saturday, July 27, 2013

According To A Recent Animal Study, Estrogen Enables Females To Respond Better To Stress

Dr. Enrique Jacome
The idea that females are more resilient than males in responding to stress is a popular view, and now University at Buffalo researchers have found a scientific explanation. The paper describing their study is published online in the high-impact journal, Molecular Psychiatry.

"We have examined the molecular mechanism underlying gender-specific effects of stress," says senior author Zhen Yan, PhD, a professor in the Department of Physiology and Biophysics in the UB School of Medicine and Biomedical Sciences. "Previous studies have found that females are more resilient to chronic stress and now our research has found the reason why."

The research shows that in rats exposed to repeated episodes of stress, females respond better than males because of the protective effect of estrogen. In the UB study, young female rats exposed to one week of periodic physical restraint stress showed no impairment in their ability to remember and recognize objects they had previously been shown. In contrast, young males exposed to the same stress were impaired in their short-term memory.

An impairment in the ability to correctly remember a familiar object signifies some disturbance in the signaling ability of the glutamate receptor in the prefrontal cortex, the brain region that controls working memory, attention, decision-making, emotion and other high-level "executive" processes.

Last year, Yan and UB colleagues published in Neuron a paper showing that repeated stress results in loss of the glutamate receptor in the prefrontal cortex of young males.

The current paper shows that the glutamate receptor in the prefrontal cortex of stressed females is intact. The findings provide more support for a growing body of research demonstrating that the glutamate receptor is the molecular target of stress, which mediates the stress response. The stressors used in the experiments mimic challenging and stressful, but not dangerous, experiences that humans face, such as those causing frustration and feelings of being under pressure, Yan says.

By manipulating the amount of estrogen produced in the brain, the UB researchers were able to make the males respond to stress more like females and the females respond more like males.

"When estrogen signaling in the brains of females was blocked, stress exhibited detrimental effects on them," explains Yan. "When estrogen signaling was activated in males, the detrimental effects of stress were blocked.

"We still found the protective effect of estrogen in female rats whose ovaries were removed," says Yan. "It suggests that it might be estrogen produced in the brain that protects against the detrimental effects of stress." In the current study, Yan and her colleagues found that the enzyme aromatase, which produces estradiol, an estrogen hormone, in the brain, is responsible for female stress resilience. They found that aromatase levels are significantly higher in the prefrontal cortex of female rats.

"If we could find compounds similar to estrogen that could be administered without causing hormonal side effects, they could prove to be a very effective treatment for stress-related problems in males," she says. She notes that while stress itself is not a psychiatric disorder, it can be a trigger for the development of psychiatric disorders in vulnerable individuals.

Tuesday, July 23, 2013

Study Shows Estrogen-Only Therapy After Hysterectomy May Be A Lifesaver

Dr. Enrique Jacome
The widespread rejection of estrogen therapy after the 2002 Women's Health Initiative (WHI) study has most likely led to almost 50,000 unnecessary deaths over the last 10 years among women aged 50 to 69 who have had a hysterectomy, Yale School of Medicine researchers reveal in a study published in the American Journal of Public Health.

Led by Philip Sarrel, M.D., emeritus professor in the Departments of Obstetrics, Gynecology & Reproductive Sciences, and Psychiatry, the researchers analyzed United States census data, hysterectomy rates, and estimates of decline in hormone use in women aged 50 to 59 between 2002 and 2011.

Before 2002, it was standard practice for doctors to recommend estrogen therapy for this slice of the population, and more than 90% of these women used it to treat symptoms such as hot flashes, and to prevent osteoporosis and other diseases related to menopausal hormone deficiency. Today, about 10% of these women use estrogen.

This sharp decline in estrogen usage was linked to results from one part of the large, federally funded WHI study in 2002. Women and their doctors became frightened of the dangers of post-menopausal hormones. But according to Sarrel and his colleagues, this was a report about women with a uterus, who took pills that combined estrogen and a progestin. Women who have a uterus must take a second hormone (a progestin) to avoid a risk of uterine cancer. But these results did not apply to women with no uterus who use estrogen-only therapy.

"Sadly, the media, women, and health care providers did not appreciate the difference between the two kinds of hormone therapy," Sarrel said. "As a result, the use of all forms of FDA-approved menopausal hormone therapy declined precipitously."

Sarrel added that for the women taking combined hormone therapy (at least the particular drug, Prempro, used in the WHI study), it was probably a good decision to avoid it because the WHI study showed a significant increase in breast cancer, heart disease, stroke, and blood clots in women who used this drug compared to placebo. However, for the women taking estrogen-only therapy, avoiding treatment does not appear to have been a good decision.

Results from the second part of the WHI study, which followed women who had no uterus and who took either estrogen-only or placebo, were very different. A series of papers published by the WHI between 2004 and 2012 showed that estrogen-only therapy had mostly positive health outcomes. For example, in 2011 and 2012 the WHI reported that women who received estrogen compared to those who received placebo had fewer deaths each year for 10 years and were less likely to develop breast cancer and heart disease. For each of the 10 years the death rate among those not taking estrogen was 13 more per 10,000. Most of these women died from heart disease while breast cancer accounted for almost all the other deaths.

"Estrogen avoidance has resulted in a real cost in women's lives every year for the last 10 years - and the deaths continue," said Sarrel. "We hope this article will stir an overdue debate and raise consciousness about the health benefits of estrogen-only therapy for women in their 50s with no uterus."

www.vivenaturalhormones.com

Tuesday, July 16, 2013

Analysis Shows Calcium And Vitamin D Help Hormones Aid Bones After Menopause

Dr. Enrique Jacome
Should women take calcium and vitamin D supplements after menopause for bone health? Recommendations conflict, and opinions are strong. But now, an analysis from the major Women's Health Initiative (WHI) trial throws weight on the supplement side - at least for women taking hormones after menopause. The analysis was published online in Menopause, the journal of The North American Menopause Society.

Among the nearly 30,000 postmenopausal women in the hormone trial, some 8,000 took supplemental calcium (1,000 mg/day) and vitamin D (400 mg/day), and some 8,000 took look-alike placebos. These women came from all the hormone groups in the study - those who took estrogen plus a progestogen (required for women with a uterus), those who took estrogen alone, and those who took the hormone look-alike placebos. The researchers looked at how the rates of hip fracture differed among women who took hormones and supplements, those who took hormones alone, and those who took neither. 

The supplements and hormones had a synergistic effect. Women using both therapies had much greater protection against hip fractures than with either therapy alone. Taking supplements alone wasn't significantly better than taking no supplements and no hormones. The benefit of hormone therapy was strong in women who had a total calcium intake (supplements plus diet) greater than 1,200 mg/day. Similarly, the benefit was strong in women who had higher intakes of vitamin D, but the individual effect of each one could not be determined because the two supplements were given together. 

The effects translated into 11 hip fractures per 10,000 women per year among the women who took both hormones and supplements compared with 18 per 10,000 women per year among those who took hormones only, 25 per 10,000 women per year among those who took supplements alone, and 22 among those who got neither therapy. 

These results suggest, said the authors, that women taking postmenopausal hormone therapy should also take supplemental calcium and vitamin D. Although they couldn't specify how much, they noted that the benefits seem to increase with increasing total intake of calcium and vitamin D. The dose will depend on keeping side effects, such as constipation from too much calcium, to a minimum, they said. 

That differs from the recommendation of the US Preventive Services Task Force (USPSTF), made earlier this year. USPSTF stated there was no basis for recommending calcium and vitamin D supplements to prevent fractures. But now, with this study, there may well be.


www.vivenaturalhormones.com

Tuesday, July 9, 2013

Study Shows Hormone Levels Are Linked To Female Psychological Disorders

Dr. Enrique Jacome
Women are more susceptible to some of the psychological effects linked to stressful experiences at specific stages in their monthly menstrual cycle, scientists from University College London reported in Neurobiology of Learning and Memory.

The authors believe common mental health problems that develop in women might be prevented if specific dates during the menstrual cycle are targeted. They say their study is the first to demonstrate a possible association between psychological vulnerability and a specific moment during the menstrual cycle - which in this case was ovulation.


Repetitive and undesirable thoughts


Repetitive and unwanted thoughts are common symptoms of mood and anxiety disorders. These intrusive thoughts typically occur after a stressful experience; sometimes for a few days, and even weeks or longer.

Dr Sunjeev Kamboj and team set out to determine how vulnerable women are to a stressful event during different stages of their menstrual cycle. The study involved 41 females aged from 18 to 35 years. They all had regular menstrual cycles, and none of them were on the contraceptive pill.

Each participant was asked to watch a 14-minute "stressful" movie which contained death or injury. Saliva samples were taken immediately afterwards so that their hormone levels could be assessed. They were then asked to write down whether they had unwanted thoughts about the video over the next few days, when they had them, and how often.

Intrusive thoughts more common during the early Luteal phase

Sunjeev Kamboj said:

"We found that women in the 'early luteal' phase, which falls roughly 16 to 20 days after the start of their period, had more than three times as many intrusive thoughts as those who watched the video in other phases of their menstrual cycle. This indicates that there is actually a fairly narrow window within the menstrual cycle when women may be particularly vulnerable to experiencing distressing symptoms after a stressful event."


The researchers say that their findings may influence how health care professionals deal with mental health problems in females, especially those who have suffered trauma.

Dr Kamboj said:

"Asking women who have experienced a traumatic event about the time since their last period might help identify those at greatest risk of developing recurring symptoms similar to those seen in psychological disorders such as depression and post-traumatic stress disorder (PTSD).

This work might have identified a useful line of enquiry for doctors, helping them to identify potentially vulnerable women who could be offered preventative therapies.

However, this is only a first step. Although we found large effects in healthy women after they experienced a relatively mild stressful event, we now need to see if the same pattern is found in women who have experienced a real traumatic event. We also need further research to investigate how using the contraceptive pill affects this whole process."

Studies have linked phases of the menstrual cycle to several mental and physical issues, including:

  • Severity of respiratory symptoms - researchers from Norway reported in the American Journal of Respiratory and Critical Care Medicine that a female's respiratory symptoms may be affected by her menstrual cycle, including asthma symptoms. They tend to get worse during the mid-luteal to mid-follicular phases.

  • Premenstrual syndrome - symptoms of PMS (premenstrual syndrome) are usually worse for women who feel stressed early on during their menstrual cycle, a team from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the University of Massachusetts-Amherst, and the State University of New York, Buffalo, reported in the Journal of Women's Health.

  • Knee injuries - researchers from the University of Texas-Austin, and the University of North Carolina-Chapel Hill, suggest that changes across the menstrual cycle in nerves that control muscle activity make female athletes more susceptible to knee injuries, especially anterior cruciate ligament tears and chronic pain. They believe knee injuries are closely linked to the menstrual cycle.

  • Impulsive spending - as their monthly period approaches, women's spending tends to become more impulsive and less controlled. A team from the University of Hertfordshire, England, reported at the British Psychological Society Annual Conference (April 2009) that hormonal fluctuations may lead to women spending more than they can afford, buying stuff they do not really want, and feeling out of control with money.

Thursday, June 27, 2013

Study Shows That After Uterus And Ovary Removal, Testosterone Therapy Improves Sexual Function

Dr. Enrique Jacome
High doses of testosterone significantly improve sexual function among women who have had their uterus and ovaries surgically removed, a clinical study demonstrates. The results were presented at The Endocrine Society's 95th Annual Meeting in San Francisco. 

Surgical removal of the uterus, or hysterectomy, and the ovaries, which is called oophorectomy, is performed to treat various diseases, including cancer. Hysterectomy is also performed as an elective sterilization, usually among older women, and may be combined with oophorectomy if ovarian disease is present. In cases of a family history of ovarian cancer, an oophorectomy of healthy ovaries may be performed in conjunction with hysterectomy to prevent future disease. 

Since the ovaries produce the hormones estrogen and progesterone, which help regulate the menstrual cycle, their removal causes a drop in these hormones. A side effect of this sudden hormonal drop is a decreased interest in sexual activity, which can disrupt intimate relationships and affect quality of life. 

There has been emerging interest in supplemental hormonal treatment with the primary male sex hormone, testosterone for disrupted sexual functioning in postmenopausal women. 

To determine whether testosterone therapy increases sexual functioning among patients who have had hysterectomy and oophorectomy, study investigators recruited 71 women who had undergone these procedures. For the first 12 weeks of the study, participants received estrogen replacement. Investigators then randomly assigned them to one of five groups for weekly injections of placebo, or 3, 6.25, 12.5, or 25 milligrams (mg) of an intramuscular testosterone medication, called testosterone enanthate, for 24 weeks. 

They found that sexual functioning significantly improved among the group of women who received 25 mg of testosterone compared to placebo. In addition, the weekly number of sexual encounters among this group increased by 2.7 encounters. These improvements were related to greater blood concentrations of free testosterone, which means that the hormone is more active because it is not bound to proteins in the blood. The groups receiving lower doses of the hormone, however, did not have improvement in sexual functioning. 

"This study provides novel information about the range of testosterone doses associated with potential beneficial effects on sexual function in women," said the study's lead author Grace Huang, M.D., endocrinology fellow at Boston University Medical Center. "However, long-term studies are needed to determine whether these improvements in sexual function can be achieved safely without increasing risk for heart disease." 

A primary concern with testosterone replacement therapy is that it can cause symptoms of masculinization among women. These symptoms include unwanted hair growth, lower voice tone, and increased muscle mass. Few of these side effects were reported in this study. 

Investigators used hormonal tests to measure blood concentrations of both total and free testosterone. To assess sexual function, they used a standard questionnaire for women. Participants also completed weekly logs to document sexual activity. 

Monday, June 24, 2013

Study Shows Testosterone Improves Verbal Learning And Memory In Postmenopausal Women

Dr. Enrique Jacome
Postmenopausal women had better improvement in verbal learning and memory after receiving treatment with testosterone gel, compared with women who received sham treatment with a placebo, a new study found. Results were presented at The Endocrine Society's 95th Annual Meeting in San Francisco. 

"This is the first large, placebo-controlled study of the effects of testosterone on mental skills in postmenopausal women who are not on estrogen therapy," said principal investigator Susan Davis, MBBS (MD), PhD, of Monash University, Melbourne, Australia. "Our study has confirmed our similar findings from two smaller studies in postmenopausal women and suggests that testosterone therapy may protect women against cognitive decline after menopause." 

Menopause has been linked with memory decline because of a decrease in levels of the protective hormone estrogen. Yet testosterone also is an important hormone in women because it has a role in sexual desire, bone density and energy while improving mood. In men, studies have shown that testosterone replacement has favorable effects on brain function. 

In this new, investigator-initiated study, the Australian researchers randomly assigned 92 healthy postmenopausal women, ages 55 to 65, who were not receiving estrogen therapy, to receive one of two treatments for 26 weeks. The treatments were a testosterone gel (LibiGel, BioSante Pharmaceuticals) applied daily to the upper arm, or a placebo, an identical-appearing gel containing none of the medication. Neither the study participants nor the investigators were aware of which gel the women received. 

Before treatment and at 12 and 26 weeks of treatment, subjects underwent comprehensive testing of their cognitive function (mental skills) using a computer-based battery of tests designed for people with normal brain function (CogState). Ninety women completed the study. The investigators found no cognitive differences between groups before the start of treatment. 

After 26 weeks, the women who received testosterone therapy had a statistically significant and clinically meaningful improvement in verbal learning and memory - how well they recalled words from a list, Davis reported. The average test score for the testosterone-treated group was 1.6 points greater than that of the placebo group. No differences between the groups were evident for any other cognitive test. 

Women receiving testosterone therapy reported no major side effects related to the gel. Their testosterone levels increased with treatment but remained in the normal female range. 

Although further study is needed in more women, Davis said the results are important. "There is no effective treatment to date to prevent memory decline in women, who are higher risk of dementia than men," she said. 


www.vivenaturalhormones.com

Wednesday, June 19, 2013

Girls With Anorexia Nervosa Suffer Reduced Anxiety With Estrogen Replacement Therapy

Dr. Enrique Jacome
Estrogen replacement therapy is associated with a significant decrease in anxietysymptoms among girls with anorexianervosa, a new clinical trial finds. The results were presented today at The Endocrine Society's Annual Meeting in San Francisco. 

"This is the first study to show that estrogen replacement ameliorates the tendency for anxiety in anorexia nervosa and may prevent increasing body dissatisfaction with weight gain," said the study's lead author Madhusmita Misra, MD, MPH, pediatric endocrinologist and associate professor of pediatrics at the Massachusetts General Hospital and Harvard Medical School in Boston, MA. "This is very important given that anorexia nervosa can be difficult to treat, and underlying anxiety, eating attitudes and concerns of body shape with increasing weight during treatment may reduce the success of treatment programs." 

Anorexia nervosa is a severe eating disorder that primarily affects teenage girls, although boys, as well as older and younger people, can also develop it. Approximately 0.2-1 percent of teenage girls suffer from the disorder. 

The disorder is characterized by a distorted body image, which causes patients to view themselves as heavy, or fat, even when their body-mass index is well below the normal range. As the disease progresses, patients become increasingly preoccupied with weight loss through restricting food and/or increasing activity with intense, frequent exercising. Some resort to purging behaviors to rid themselves of any food that they consume. 

Complications include depression, increased risk of suicide and weakened bones, which increase the risk of fractures and osteoporosis. Among girls, menstrual periods stop occurring as body weight and estrogen production drop. If left untreated, the disorder can cause death. Unfortunately, anorexia can be quite difficult to treat, and relapse is common. 

In this study, investigators found that anxiety scores on a standardized questionnaire decreased as estrogen levels increased. This relationship was unaffected by weight gain. Additionally, if weight gain did occur, estrogen replacement appeared to prevent a worsening of attitudes toward body image and food, as assessed using the Eating Disorders Inventory-II questionnaire. 

"Identification of therapies that reduce the tendency to experience anxiety and reduce body dissatisfaction with weight gain may have a major impact in reducing relapse," Misra said. "These findings have the potential to impact therapy in anorexia nervosa with early implementation of estrogen replacement in girls who are estrogen deficient." 

Participants included 72 teenage girls diagnosed with anorexia nervosa. At the start of the study, all were between 13 and 18 years old, and had a measured bone age of at least 15 years. 

Investigators randomly assigned participants to receive estrogen or placebo for 18 months. Of the 72 initial participants, 38 received estrogen and 34 received placebo. At the study's start and end, participants completed questionnaires designed to assess anxiety, and attitudes toward eating and body image. Thirty-seven participants completed the study, with 20 receiving estrogen and 17 receiving placebo.


www.vivenaturalhormones.com